Download Report

Ask your Consero representative
about our new membership platform.
IP Forum For
Pharmaceuticals
& Biotechnology
20–22 April 2015
Mövenpick Hotel Egerkingen
Höhenstrasse 12
4622 Egerkingen
Switzerland
conser.ro/1v06AZF
consero.ie | #ConseroIP
About The Forum
As Chief IP and Patent Counsel in the Pharmaceutical and Biotechnology industry,
your IP strategy has a significant and direct impact on the growth of your company.
Your strategy must play an offensive and defensive role in protecting your IP
assets both at home and in foreign markets. It must allow you to act quickly and
aggressively when high-stakes threats arise. And, your global IP strategy must be
nimble during a period of significant change in patent law, allowing you to adjust
your sights routinely on the shifting landscape of IP in 2015 and beyond.
Consero’s 2015 IP Forum For Pharmaceuticals & Biotechnology will address
current legal and business challenges faced by today’s Chief IP and Chief Patent
Counsel, providing a unique opportunity to share best practices and strategies
that will help lead their departments and companies in the right direction.
TOPICS FOR DISCUSSION
»» What Is Your Five-Year IP Plan?
»» Having Your Cake And Eating It Too:
Protecting Global IP While Sticking To
Budget
»» Research And Development In A
Continuously Evolving Industry
»» A Year In Review: Key Cases To Examine
In 2015
2
consero.ie | #ConseroIP
AGENDA KEY
General Session
General Sessions address
top-of-mind issues in a
conversational exchange
among two or more corporate
executives and other industry
thought leaders, enabling
participants to share experience,
expertise, leadership skills, and
practical tools.
KnowledgeBridge™
Consero’s KnowledgeBridge™
sessions facilitate advanced,
high-level dialogue in an
informal boardroom-style setting
on specific topics that are
particularly suited to intimate
group discussions.
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
Forum Agenda
MONDAY, 20 APRIL
15:00–16:00
Having Your Cake And Eating It Too: Protecting
Global IP While Sticking To Budget
13:30–14:00
Opening Remarks
»» How do you evaluate your need for full protection of your global IP
portfolio against what you can afford?
14:00–15:00
What Is Your Five-Year IP Plan?
»» Where do you see your organisation’s IP program in five years, and
how do you plan on getting there?
»» What unique strategies have you used to “weatherproof” your plan
while maintaining the necessary flexibility to respond to IP issues as
they arise?
»» What are the greatest obstacles facing your five-year plan? What
proactive strategies are you using to overcome them?
»» Does it make sense to keep all patent drafting in house? In Europe?
Bernd Hutter
Dr. Judy Jarecki-Black
Head of Intellectual Property
Global Head, Intellectual
Property
MorphoSys
Merial
Andrea Macchetta
Michael Kompter
Deborah Prince
Senior Patent Counsel
General Counsel and Company
Secretary
Boehringer Ingelheim
GmbH
»» What are some creative ways to reassess your overall IP portfolio to
identify which of your patents will contribute to the company’s bottom
line? What criteria do your consider prior to determining in which
global markets to file your intellectual property?
Director, Intellectual Property
Capsugel
British Heart Foundation
Holger Seitz
Head of Global Patents
Animal Health
Boehringer Ingelheim
Pharma GmbH&Co.KG
3
consero.ie | #ConseroIP
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
MONDAY, 20 APRIL
17:00–18:00
Research And Development In A Continuously
Evolving Industry
16:00–17:00
How To Win: Modeling The Best Litigation Strategy
Complexity, risks, transnational differences, and the investments in time
and costs of IP litigation can be frustrating or rewarding. Do you have a
litigation strategy at all? Or do you find yourself improvising on a case-bycase basis?
»» How do you know if you are always involving the right parties?
»» How have you been able to leverage recent cases and rulings to
bolster inventive R&D efforts at your company?
»» What metrics do you use to evaluate the ROI of sourced R&D? Is it
worth the financial risk?
»» What new measures have you taken to encourage in-house R&D, and
how can you continue to recruit and retain top R&D talent?
»» How do you determine where to litigate?
»» How do you determine whether to take the lead or not?
»» What best practices can you share regarding other general strategic
considerations (e.g., time and money, litigation/arbitration versus
direct settlement, etc.)?
»» Have you prepared yourself enough to handle future litigation?
Europe?
Jim Kastenmayer
Graham Stuart
Senior Director, Patents
Global Head of Patents
AstraZeneca
Novartis Institutes for
Biomedical Research
18:00–18:45
Welcome Cocktail Reception
MODERATORS:
Jürg Simon
Lara Dorigo
18:45–22:00
Head of IP Practice and
Partner
Counsel
Networking Dinner
Lenz & Staehelin
4
consero.ie | #ConseroIP
Lenz & Staehelin
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
TUESDAY, 21 APRIL
10:00–11:00
KnowledgeBridge™
7:00–7:50
Networking Breakfast
11:00–12:00
Navigating A Shifting Pharmaceutical Paradigm
8:00–9:00
Actionable Insights: Taking A Deeper Dive Into
Your IP Litigation Strategy
»» What is the current global landscape for pharmaceutical and
biopharmaceutical IP litigation?
»» How do you most effectively decide when to settle, and what different
factors do you typically consider?
»» How do differences in patent law and damages calculations across
geographies affect your patent strategy when considering where and
when to bring a lawsuit?
»» What metrics and data do you analyse to determine the most
qualified outside counsel?
»» How do such differences affect your strategy when your firm is a
defendant?
»» What best practices can you share with your patent prosecution
team to ensure the most defensible patents, given the inevitability of
patent litigation?
»» What considerations, including antitrust considerations, influence
decisions of whether or not to settle a patent case and the terms of
the settlement?
Ellen Broug
Marcus Dalton
Robert Barker
Dorian Immler
Head of Intellectual Property
Vice President, Global Head,
Patents GSK Biologicals
Chief IP Counsel, Biologics
Chief Patent Counsel
GlaxoSmithKline
Medtronic Sofamor Danek,
USA, Inc.
Bayer IP GmbH
Galit Gonen
Jean-Marc Ligibel
Dr. Judy Jarecki-Black
MODERATOR:
Vice President and General
Counsel
Head of Intellectual Property
Global Head, Intellectual
Property
Christine Meyer
Merial
NERA Economic Consulting
Merus
Teva
MODERATOR:
Vifor Pharma
Senior Vice President
MaryAnne Armstrong
Partner
Birch Stewart Kolasch &
Birch LLP
5
consero.ie | #ConseroIP
12:00–12:45
Networking Luncheon
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
TUESDAY, 21 APRIL
15:00–16:00
KnowledgeBridge™
13:00–14:00
Over The Horizon: A Truly Unified Patent System?
»» What does the introduction of the Unified Patent Court mean for
Pharmaceuticals and Biotechnology in 2015?
»» How has the planned implementation of the Unitary Patent System
changed your approach to the patent process? What implications
does the new system have on your organisation overall?
»» What innovative tricks have you considered using under the new
system?
Prashant Bhavar
Christoph Rehfuess
Head of Intellectual Property
Director, Intellectual
Property, Legal &
Commercial
Rhizen Pharmaceuticals
S.A.
MODERATOR:
Head of Corporate
Intellectual Property
Daniel Neuman
Valneva
A Year In Review: Key Cases To Examine In 2015
»» What cases and rulings have been keeping you up over the past year,
and which will you be watching in 2015 and beyond?
Seth Fidel
Lead Intellectual Property
Counsel
Merrimack Pharmaceuticals
18:00–22:00
MagForce Nanotechnology
Adrian Spillmann
16:30–17:30
Networking Dinner And Entertainment
Chemical & Materials Group
Leader
Global Prior Art
6
consero.ie | #ConseroIP
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
WEDNESDAY, 22 APRIL
9:00–10:00
Crafting A Win-Win Scenario: Executing Effective
Mergers And Acquisitions
7:00–7:50
Networking Breakfast
»» What criteria do you consider when deciding with which companies to
partner?
8:00–9:00
Getting The Most Bank For Your Buck: Managing
Outside Counsel Efficiently
»» How do you negotiate with outside counsel to maintain high-quality
legal services, while staying within budget?
»» What resources do you use to determine the ROI on your outside
counsel?
»» What role should in-house and outside counsel play in designing and
implementing your strategy?
Sally Mannion
Henrik Mathiassen
Senior Corporate Counsel
Head of Patent Department
Zoetis
Zealand Pharma
»» What innovative strategies are you using during M&A discussions?
Which strategies have been most and least successful for your
company?
»» How do you manage your IP department effectively and without
distraction during a period of transition or consolidation?
Pierre Diebolt
Head of Industrial Property
Competitive & Scientific
Intelligence
Galderma
Richard Summersell
Head of Intellectual Property
Vectura Group plc
7
consero.ie | #ConseroIP
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
WEDNESDAY, 22 APRIL
10:00–11:00
Moving Towards An Integrated Corporate IP
Strategy
»» How do you better incorporate your IP team into the business as a
whole?
»» How do you work with your management team to ensure your IP
strategy successfully aligns with the overall business strategy?
»» What are some best practices to communicate your IP strategy
effectively to those in the company who lack a legal background?
Zdenek Cerman
Tony Dolan
Head of Intellectual Property
Liaison
Director of Intellectual
Property
Sanofi
BTG International Ltd.
Charlotte Retzler
Birgitte Stephensen
Senior Vice President,
Intellectual Property
Senior Vice President, IPR
and Legal
Ipsen
Genmab A/S
Kamilla Winther
Director
Novo Nordisk
12:00–13:00
Networking Luncheon
8
consero.ie | #ConseroIP
20–22 April 2015 | Mövenpick Hotel Egerkingen | IP Forum For Pharmaceuticals & Biotechnology
The Consero Model VS.
A Traditional Conference
Most conferences have
attendees with little in
vs.
common.
Most conferences rely on
lectures with “Death by
With Consero, you will be
among a select group of
senior-level executives.
With Consero, the sessions
vs.
PowerPoint.”
are discussion-based with
content driven by you and
your industry colleagues.
Much of the value of many
With Consero, you have the
conferences lies in free
opportunity to meet one-on-
branded pens and keychains
from a sea of vendor
booths.
vs.
one with best-in-class service
providers selected by you
and your peers.
The Result: A conference model that works.
With Consero, you will never look at a traditional conference the same way.
9
consero.ie | #ConseroIP
EeTtHhEe
Ee
SS
Y
STOR@
L
U
FfullLstoery
o
r
onso.com
oncserm
c@
.co
20–22 April 2015
| Mövenpick Hotel Egerkingen
| IP Forum For Pharmaceuticals
& Biotechnology
/ConseroGroup
@ConseroGroup
/Company/Consero-Group